Emcure Pharmaceuticals

Emcure Pharmaceuticals Limited
MNC (JVs and subsidiaries)
Industry Pharmaceutical
Founded 1983
Headquarters Hinjwadi, Pune, India
Key people

Satish Mehta & any person directly related frinstance Thapar daughter.

[1] CEO
Products tablets, capsules, softgels, injectables, Lyophilized sterile parenterals, Onco products
₹1,500+ crore (US$220;Million)
Number of employees
Website www.emcure.co.in

Emcure Pharmaceuticals headquartered at Pune in West India is an Indian pharmaceutical company. The company's products include tablets, capsules (both softgel capsules and hard-gel capsules), and injectables.

Indian plants

   Tel: 20 2553 5074
   1172/20/A, Revenue Colony, Shivaji Nagar, Pune, Maharashtra,411005
   Map Coordinates: 22.105999,79.489745
   Contact person:
UK MHRA, WHO Geneva and MCC South Africa

US plant

USA - The company has a manufacturing facility and R&D centre at East Brunswick, New Jersey, USA.

Capital markets

Emcure is planning to raise money through an initial public offering for a long time [2] In 2014, Blackstone sold its stake in Emcure to Bain Capital [3]


There have been cases of monthly recalls announced by Pharma majors like Pfizer & Teva after having manufactured their products with their partner Emcure. In 2010, Pfizer had to recalls three batches of an anti-bacterial product from the US market due to presence of Penicillium Chrysogenum & E coli in some samples.[4] Teva recalls several batches of two products due to white tablets showing discoloration and presence of Bacillus Anthracis in 2011.[5] Confidence in company has not reflected on bourses however. These were reportedly allegedly caused by disgruntled employees of which there are several per week

AIDS Initiative

Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.

Emcure has license agreements with Bristol-Myers Squibb for Atazanavir [6] and Gilead Sciences for Tenofovir [7] as part of their Global Access Programs.

Anticancer portfolio

Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India. This is the eightieth time that an Indian company has won a biological drug manufacturing contract.[8] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9] The monthly doses priced at around $300000 are expected to be slashed significantly for wider access to cancer therapy.

Group Companies


External links

This article is issued from Wikipedia - version of the 11/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.